$LBRX News

LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

LB Pharmaceuticals Q1 EPS $(0.67) Beats $(0.75) Estimate

HC Wainwright & Co. Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $45

LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia

LB Pharmaceuticals Announces Publication Of Phase 2 Clinical Trial Data For LB-102 In The Journal Of The American Medical Association, Psychiatry

LB Pharmaceuticals Announces Publication Of Phase 2 Clinical Trial Data For LB-102 In The Journal Of The American Medical Association, Psychiatry

LB Pharmaceuticals Inc (LBRX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

LB Pharmaceuticals Highlights LB-102 Phase 3 Schizophrenia Path, Funding Runway to 2029 at Needham

Craig-Hallum Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $36

LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare Conference

LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102’s Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)

LB Pharmaceuticals Reports Phase 2 Data Showing LB-102 Directly Improves Cognitive Function In Schizophrenia Patients

Stifel Maintains Buy on LB Pharmaceuticals, Raises Price Target to $40

LB Pharmaceuticals Inc.: Q4 Earnings Snapshot

LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

LB Pharmaceuticals Q4 EPS $(0.45) Beats $(0.63) Estimate.

LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia

LB Pharmaceuticals Starts Its Pivotal Phase 3 Study Of LB-102 To Treat Schizophrenia

LB Pharmaceuticals CEO Maps LB-102 Milestones, Says Pipeline Fully Funded Into Q2 2029

LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors